CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gyroscope Therapeutics Holdings Ltd(ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gyroscope Therapeutics Holdings Ltd(ADR)
Stevenage Bioscience Catalyst
Gunnels Wood Road
Phone: +44 1438906770p:+44 1438906770 STEVENAGE, SG1 2FX  United Kingdom
This company was Merged or Acquired on 2/18/2022.
This is a Subsidiary, click here for the Parent Company
Business Summary
Gyroscope Therapeutics Holdings plc, formerly Gyroscope Therapeutics Holdings Limited, is a clinical-stage gene therapy company. The Company develops gene therapy beyond rare diseases. It offers therapies to treat diseases of the eye that cause vision loss and blindness. The Company’s investigational gene therapy, GT005, is in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a cause of blindness. The Company develops a pipeline of recombinant adeno-associated virus (rAAV), vector-based gene therapy candidates targeting genetic variants in the pathway to be key drivers of AMD. Its gene therapies are designed as one-time treatments. The Company’s lead programs, GT005 and GT011, focus on two key targets such as Complement Factor I (CFI) and factor H like-1 (FHL1), a variant of Complement Factor H (CFH). Its gene therapy, GT005, is designed to restore balance to a system by production of CFI, a regulatory protein.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202012/31/2020YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer Jason M.Brooks 51 2/17/2022 2/17/2022
Managing Director Marie- Andree R.Gamache 48 6/29/2022 6/29/2022
Company Secretary Timothy W.Robinson 6/20/2022 6/20/2022
Director Chinmay U.Bhatt 50 11/14/2023 11/14/2023

Business Names
Business Name
GYROSCOPE THERAPEUTICS LTD
VISN

General Information
Number of Employees: 167 (As of 3/31/2021)
Outstanding Shares: 29,229,659 (As of 12/31/2020)
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, October 29, 2024